The pros and cons of weight loss injections, laid out plainly

What the evidence says these injections can do

The clearest argument in favour of weight loss injections is the clinical data behind them. In the SURMOUNT-1 trial, adults taking tirzepatide at its highest studied dose lost around 20–21% of their body weight on average over 72 weeks, results that shifted what clinicians thought was achievable with a medicine alone. Semaglutide (Wegovy) produced average reductions of around 15% over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. Both figures come from large, rigorous trials, not small observational studies.

For many people, that scale of change is not achievable through diet and activity alone, particularly where biology is working against them. Weight is shaped by hormones, genetics and metabolic set-points, a fact that the evidence on obesity has made increasingly clear. GLP-1 and dual GIP/GLP-1 medicines work on appetite-regulating pathways in the gut and brain, reducing hunger and slowing how quickly the stomach empties. The result, for people who respond well, is that eating less stops feeling like a constant battle.

NICE recommends tirzepatide for eligible adults with obesity and weight-related health conditions, and the broader trial programme involved thousands of participants across the SURMOUNT series. That breadth of evidence is part of why these medicines have received full UK marketing authorisations, not just speculative interest.

The downsides: side effects and what they mean in practice

A question our prescribers hear most weeks is some version of: "The nausea sounds bad, is it worth it?" It is a fair thing to ask. The most common side effects of both tirzepatide and semaglutide are gastrointestinal: nausea, loose stools, constipation, indigestion, burping and, for some people, vomiting. These are not rare. They are the reason treatment starts at the lowest dose and is increased gradually by your prescriber.

For most people, the worst of it clusters around the first few weeks and after each dose step-up, then settles. For some, it does not settle fully, or the side effects are significant enough to pause or stop treatment. That is a real possibility to factor in. The full picture of what these injections involve on harder days is worth reading separately if you want to go deeper.

More serious but infrequent risks include acute pancreatitis. The MHRA highlighted this in a January 2026 Drug Safety Update, asking patients to seek urgent medical attention for severe stomach pain that radiates to the back, with or without vomiting. Gallbladder problems and dehydration from severe gastrointestinal illness are also noted. These are not reasons to avoid the medicines for eligible people; they are reasons to be under clinical supervision rather than obtaining them casually. The NHS medicines page for tirzepatide covers the full side-effect profile clearly.

Practical realities: injections, routine and cost

Once a week, you inject a small pen into the abdomen, thigh or upper arm and rotate the site. Many people find the mechanics less daunting than they expected; the pens are pre-filled and designed for self-administration. Storage means keeping the pen in the fridge, and disposing of it properly matters, a sharps container is the correct way to do that at home.

What is harder to paper over is the cost. Private treatment is priced per pen, per month, and it is not inexpensive. Since Eli Lilly raised UK list prices in September 2025 (the highest tirzepatide dose now has a list price of around £330 per four-week pen) the private market reflects that shift. For context on what to expect and what different price points actually include, the page on how much weight loss injections cost in the UK breaks this down carefully. There is no NHS shortcut for most people yet; the phased rollout means strict criteria and long waits for many. That gap is exactly why regulated private services exist.

The injection route also simply does not suit everyone. Some people have needle anxiety that does not resolve. Some have conditions that contraindicate these medicines, and if you are wondering whether a hormone-based treatment such as Prostap might affect your weight, what the evidence says about Prostap injections and weight loss is a useful starting point. Oral semaglutide (Wegovy tablets) is now MHRA-approved, which opens an alternative for people who prefer not to inject, though that is a conversation for a prescriber, not a decision to make alone.

Who this decision belongs to, and how a prescriber frames it

The pros and cons of weight loss injections are not abstract: they land differently depending on your health history, your starting point, your other medicines, and what you are trying to achieve. For someone with sleep apnoea, hypertension and a BMI above 35, the clinical calculus looks different from someone with a BMI of 28 and no comorbidities, even though both might technically meet eligibility criteria on paper.

Specific situations shift the picture further. People with PCOS, for instance, often have a different relationship with insulin resistance and appetite regulation, how injections intersect with PCOS is a question worth exploring with a clinician who understands both. People living with MS face additional considerations around fatigue and mobility, and how weight loss injections interact with MS is something a prescriber familiar with the condition can help you think through carefully. Access is not equal across the country either; disparities in who can actually get these medicines affect real decisions for real people.

A prescriber's job is to sit with all of that (your history, your goals, the contraindications) and give you an honest view, not a sales pitch. That is why this category of medicine requires a prescription in the first place. If you want to talk it through, our prescribers are available seven days a week.